A Phase I Study of TS-1 in Combination with ABI-007 every three weeks in Patients with Unresectable or Recurrent Gastric Cancer
Phase 1
- Conditions
- nresectable or Recurrent gastric cancer
- Registration Number
- JPRN-jRCT2080221526
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Signed, written informed consent.
- Patient has a histologically or cytologically confirmed gastric adenocarcinoma. Or patient has a clinically confirmed unresectable or recurrent gastric cancer.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Exclusion Criteria
- Patient who is contraindicated to TS-1 or Paclitaxel.(Refer to Package Insert).
- Patient has multiple cancer.
- Patient has a clinically significant medical history or disease complication.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method